Saturday 17 October 2026
Export ATHE’s income statement to Excel — free account
Alterity Therapeutics Limited - Sponsored ADR
ATHE Healthcare Biotechnology
Revenue growth for five consecutive years; insiders bought in the last twelve months.
2.62
0.10
−3.68%
Follow ATHE
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 16.50 | 10.90 | 7.80 | 2.80 | 6.80 | 2.90 | 1.55 | 1.00 | 2.52 | 2.35 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | 45.80 | 32.80 | 27.20 | 51.50 | 27.50 | 12.30 | 5.41 | 3.88 | 7.00 | 5.89 | |||||
| People | |||||||||||||||
| People | Employees | 9 | 14 | 14 | 12 | 11 | 12 | 12 | 10 | 9 | 9 | ||||
| Revenue/emp, $m | 0.26 | 0.18 | 0.26 | 0.01 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 2 | 3 | 4 | 0 | 3 | — | — | — | — | — | ||||
| Gross margin, % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (6) | (6) | (9) | (9) | (11) | (9) | (9) | (13) | (8) | (16) | |||||
| EBT margin, % | (239.05) | (248.45) | (243.84) | (9,623.22) | (339.76) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (6) | (6) | (9) | (9) | (11) | (9) | (9) | (13) | (8) | (16) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 2.67 | 2.90 | 3.53 | 0.06 | 1.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (6.40) | (7.00) | (8.40) | (6.24) | (4.04) | (2.32) | (2.31) | (2.02) | (0.74) | (0.91) | |||||
| Cash flow | (4.97) | (5.44) | (9.72) | (4.25) | (4.58) | (2.23) | (3.33) | (1.36) | (0.70) | (0.87) | |||||
| Capex | (0.02) | (0.05) | 0.00 | (0.01) | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (4.99) | (5.49) | (9.73) | (4.25) | (4.58) | (2.25) | (3.33) | (1.36) | (0.70) | (0.87) | |||||
| Book value | 20.07 | 14.01 | 11.54 | 3.22 | 8.05 | 6.42 | 3.80 | 1.49 | 2.58 | 1.65 | |||||
| Shares, m | 1 | 1 | 1 | 1 | 3 | 4 | 4 | 6 | 11 | 18 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | ||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | |||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | |||||
| EV/Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | |||||
| EV/FCF | 1.06 | 1.10 | 0.49 | 0.31 | 1.73 | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (4) | (5) | (10) | (6) | (13) | (9) | (13) | (8) | (7) | (15) | ||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | |||||
| Free cash flow | (4) | (5) | (10) | (6) | (13) | (9) | (13) | (8) | (7) | (15) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 18 | 12 | 12 | 5 | 23 | 26 | 15 | 9 | 27 | 29 | ||||
| Total debt | — | — | — | 0 | 0 | 0 | 0 | — | — | — | |||||
| Net debt | (16) | (12) | (10) | (6) | (21) | (25) | (11) | (8) | (21) | (25) | |||||
| Shareholders’ equity | 18 | 12 | 12 | 5 | 23 | 26 | 15 | 9 | 27 | 29 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (26.06) | (38.17) | (61.37) | (86.50) | (72.06) | (33.83) | (38.41) | (80.92) | (37.10) | (52.04) | ||||
| ROIC | (229.92) | (574.31) | (358.62) | 0.00 | (396.76) | (1,656.09) | (154.05) | (1,248.22) | (135.49) | (327.72) | |||||
| ROE | (27.93) | (42.26) | (72.60) | (108.60) | (82.99) | (38.44) | (45.24) | (102.77) | (43.10) | (56.26) | |||||
Negative figures in brackets.
Fiscal years to Jun 2021
Charts ten years each
Alterity Therapeutics Limited - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio, Inc. | $54.3M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| RNTX Rein Therapeutics Inc. | $54.2M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +115.40% (above 0%: growing) | n/m | −27.63% (below 0%: shrinking) | 84.27% | (368.43%) | Compare |
| BOLD Boundless Bio, Inc. | $53.5M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | Compare |
| ATHE Alterity Therapeutics Limited - Sponsored ADR | $52.0M | — (loss-making) | — | — | 0.00% | −84.83% (below 0%: shrinking) | 0.00% | — | |
| INKT MiNK Therapeutics, Inc. | $50.7M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LONA LeonaBio, Inc. | $49.8M | — (loss-making) | — | — | n/m | −142.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CRBU Caribou Biosciences, Inc. | $49.8M | — (loss-making) | — (loss-making) | −43.79% (below 0%: shrinking) | n/m | −33.16% (below 0%: shrinking) | 100.00% | (1,690.39%) | Compare |
| MREO Mereo BioPharma Group plc - Sponsored ADR | $49.3M | — (loss-making) | — (loss-making) | — | n/m | +21.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $52.1M | — | — | −19.59% | — | −32.94% | 0.00% | 0.00% |
Alterity Therapeutics Limited - Sponsored ADR (ATHE) key facts
- Alterity Therapeutics Limited - Sponsored ADR (ATHE) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of October 16, 2026, ATHE traded at $2.62, a market capitalization of $52.0 million.
- Return on equity was −56.3% and debt-to-equity 0.00.